On Tuesday 12 May 2026, the Department for Science, Innovation and Technology said Isomorphic Labs had become the latest company to receive investment from the UK Government’s Sovereign AI Fund. The backing forms part of a wider financing round announced the same day by the London-founded business, which said it had raised $2.1 billion in Series B funding with the UK Sovereign AI Fund among the participants. (gov.uk) In policy terms, the move is an equity intervention inside a private market round rather than a conventional grant award. DSIT’s language and Sovereign AI’s published mission indicate that the purpose is to help strategically important AI firms remain and scale in the UK, even when they are already able to attract global capital. (gov.uk)
Isomorphic Labs was launched in 2021 by Sir Demis Hassabis and is headquartered in London. The company says it builds on AlphaFold and now operates a unified AI drug design engine, IsoDDE, across multiple therapeutic areas and drug modalities; in February 2026 it said the system more than doubled AlphaFold 3’s accuracy on a protein-ligand structure-prediction generalisation benchmark and improved binding-affinity prediction at lower time and cost. (isomorphiclabs.com) That technical claim is central to the public case for investment. The government is backing a company that argues AI can shorten and improve early-stage medicine design, not simply automate administrative tasks, and it is doing so in a sector where the UK already has recognised research strength and established pharmaceutical relationships. (gov.uk)
Sovereign AI itself is a new state-backed venture vehicle. It was launched on 16 April 2026 with up to £500 million of government funding, and its public offer combines equity investment with access to supercomputing, fast-track visas, datasets, procurement routes and direct engagement with government. Typical equity cheques are described by DSIT as around £1 million to £10 million. (gov.uk) The Isomorphic Labs decision therefore shows the intended design of the instrument. The state is not attempting to replace private investors in company building at scale; it is entering rounds on market terms and adding assets that private capital cannot supply, especially compute capacity and administrative support for specialist recruitment. That conclusion is drawn from Sovereign AI’s published offer. (sovereignai.gov.uk)
DSIT said the Isomorphic Labs announcement takes Sovereign AI to three equity investments since launch, with nine companies backed overall once compute access is included. At launch, the unit said it had already made its first equity investment in Callosum and had deployed more than 3 million GPU hours through the AI Research Resource to six frontier AI companies. (gov.uk) The early portfolio points to a selective industrial strategy rather than a broad startup support scheme. Sovereign AI’s published material highlights frontier AI applications in compute, life sciences, defence and other areas the government treats as economically or strategically significant. That is an inference from the companies named in the fund’s first announcements and mission documents. (sovereignai.gov.uk)
For life sciences, the significance is that Isomorphic Labs is no longer only a research story. The company has announced collaborations with Eli Lilly, Novartis and Johnson & Johnson, and its May 2026 Series B statement said the new capital would scale the AI drug design engine, expand the business globally and advance its drug candidate pipeline. (isomorphiclabs.com) That gives the state a clearer policy rationale for participation. If a UK-based company can keep its intellectual property, high-value jobs and later-stage commercial activity anchored domestically, ministers can present Sovereign AI as a tool for retaining more value from British research rather than simply celebrating laboratory breakthroughs that are monetised elsewhere. That is an inference based on the fund’s stated aim of keeping jobs, growth and innovation in the UK. (gov.uk)
The announcement does not create an immediate new treatment, regulatory approval or NHS procurement pathway. It does show that the UK state is prepared to treat frontier drug-design AI as strategically important enough for direct participation in company finance, alongside the wider offer of compute, talent and government access. (gov.uk) For readers tracking industrial strategy, the Isomorphic Labs deal is best read as an early test of whether Sovereign AI can do what ministers say it is designed to do: identify a small number of high-potential firms, join rounds quickly and keep the next generation of AI capability growing from Britain. The measure of success will come later in follow-on investment, research output, job creation and, in this case, whether AI-designed candidates make it into the clinic. (gov.uk)